Profile data is unavailable for this security.
About the company
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.
- Revenue in DKK (TTM)14.31bn
- Net income in DKK3.24bn
- Incorporated2000
- Employees6.46k
- LocationNovozymes A/SKrogshoejvej 36BAGSVAERD 2880DenmarkDNK
- Phone+45 44460000
- Fax+45 44469999
- Websitehttps://www.novozymes.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clariant AG | 37.21bn | -20.43m | 45.33bn | 17.79k | -- | 2.68 | 20.54 | 1.22 | -0.009 | 0.082 | 16.57 | 7.47 | 0.6851 | 4.44 | 5.98 | 305,178.50 | 0.1505 | 3.34 | 0.2136 | 4.84 | 29.71 | 29.94 | 0.2197 | 4.35 | 0.8747 | -- | 0.4712 | 61.94 | 3.86 | 1.74 | 45.26 | 2.49 | -4.23 | 8.85 |
| Arkema SA | 66.03bn | 4.41bn | 48.61bn | 20.00k | 11.03 | 1.28 | 5.62 | 0.7362 | 7.70 | 7.70 | 115.47 | 66.45 | 0.8771 | 5.74 | 6.30 | 441,929.00 | 6.26 | 5.12 | 7.76 | 6.35 | 21.75 | 20.84 | 7.14 | 5.61 | 1.40 | 7.55 | 0.3406 | 34.68 | 5.89 | 7.65 | 24.81 | 32.03 | 3.59 | 6.96 |
| Johnson Matthey PLC | 91.02bn | 3.50bn | 51.23bn | 12.99k | 14.58 | 2.32 | 10.36 | 0.5629 | 2.14 | 2.14 | 55.76 | 13.49 | 1.95 | 8.69 | 7.52 | 827,302.10 | 7.49 | 8.09 | 11.10 | 11.47 | 9.46 | 8.08 | 3.84 | 3.43 | 1.00 | 12.84 | 0.3343 | 56.15 | 4.58 | -0.7465 | 38.59 | 3.95 | 7.09 | 5.26 |
| Uralkaliy PAO | 20.11bn | 4.83bn | 51.71bn | 20.50k | 3.29 | 1.42 | 7.76 | 2.57 | 36.20 | 36.20 | 148.57 | 83.76 | 0.3621 | 5.06 | 8.36 | -- | 8.71 | 4.72 | 12.55 | 6.31 | 75.52 | 75.89 | 24.05 | 15.21 | 0.4072 | -- | 0.7517 | 0.00 | 7.88 | 10.40 | -117.49 | -- | 10.58 | -- |
| Brenntag AG | 95.55bn | 3.49bn | 53.62bn | 16.98k | 15.35 | 2.21 | 10.27 | 0.5612 | 3.03 | 3.03 | 82.98 | 21.01 | 1.59 | 8.31 | 6.46 | 770,125.20 | 5.81 | 5.50 | 8.36 | 7.61 | 20.98 | 21.30 | 3.66 | 3.43 | 1.18 | 8.04 | 0.4446 | 40.27 | 6.87 | 5.14 | 27.74 | 6.32 | 12.68 | 6.73 |
| Novozymes A/S | 14.31bn | 3.24bn | 70.54bn | 6.46k | 26.58 | 7.77 | 16.06 | 4.93 | 11.19 | 11.19 | 49.41 | 38.28 | 0.7355 | 2.26 | 5.25 | 2,334,203.00 | 16.65 | 16.14 | 22.69 | 20.53 | 56.29 | 57.86 | 22.63 | 21.21 | 0.7527 | 21.78 | 0.2967 | 40.24 | -0.9703 | 4.14 | 3.43 | 7.96 | 12.11 | 14.87 |
| Chr Hansen Holding A/S | 8.60bn | 1.83bn | 74.21bn | 3.15k | 40.50 | 11.86 | 32.13 | 8.63 | 13.90 | 13.90 | 65.19 | 47.47 | 0.6024 | 3.14 | 6.61 | 2,728,721.00 | 12.85 | 11.71 | 15.48 | 13.85 | 55.80 | 53.39 | 21.33 | 19.70 | 0.8063 | 16.04 | 0.4913 | 73.71 | 3.28 | 8.25 | 1.88 | 10.61 | 8.73 | 14.69 |
| Evonik Industries AG | 105.04bn | 5.45bn | 80.03bn | 35.81k | 14.68 | 1.45 | 6.50 | 0.7619 | 1.57 | 1.72 | 30.19 | 15.82 | 0.6832 | 4.61 | 7.79 | 390,311.60 | 3.66 | 4.49 | 4.47 | 5.48 | 29.22 | 31.10 | 5.35 | 5.91 | 1.10 | 8.60 | 0.3898 | 65.64 | 4.46 | 3.41 | 30.43 | 8.24 | -0.9601 | 2.83 |
| Yara International ASA | 89.48bn | 3.91bn | 82.49bn | 16.76k | 21.11 | 1.38 | 8.64 | 0.9219 | 19.05 | 19.05 | 435.40 | 291.56 | 0.766 | 3.99 | 7.50 | 7,090,022.00 | 3.22 | 4.99 | 4.23 | 6.29 | 24.52 | 25.45 | 4.21 | 5.74 | 0.764 | 50.00 | 0.3228 | 93.88 | 13.82 | -2.24 | -66.67 | -30.49 | 7.70 | -15.06 |
Data as of Sep 20 2019. Currency figures normalised to Novozymes A/S's reporting currency: Danish Krone DKK
17.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 31 Dec 2017 | 12.56m | 5.30% |
| The Vanguard Group, Inc.as of 31 Jul 2019 | 5.79m | 2.44% |
| Invesco Advisers, Inc.as of 30 Jun 2019 | 4.44m | 1.87% |
| Putnam Investment Management LLCas of 31 Mar 2019 | 3.59m | 1.51% |
| MFS International (UK) Ltd.as of 31 Jul 2019 | 3.11m | 1.31% |
| Harding Loevner LPas of 31 Jul 2019 | 3.11m | 1.31% |
| Norges Bank Investment Managementas of 31 Dec 2018 | 3.10m | 1.31% |
| BlackRock Fund Advisorsas of 05 Sep 2019 | 2.64m | 1.11% |
| Walter Scott & Partners Ltd.as of 30 Jun 2019 | 2.15m | 0.91% |
| NNIP Advisors BVas of 31 Mar 2019 | 2.13m | 0.90% |
More ▼
Data from 31 Dec 2018 - 30 Aug 2019Source: FactSet Research Systems Inc.
